Inhibrx
INBX
Inhibrx (INBX) news
Recent news
Inhibrx Biosciences shares fall 22% after co releases data from mid-stage study of its experimental combination cancer drug
AInvest Wire · Sep 8, 2026Inhibrx shares resume trading, falls 4.2% after trial results
AInvest Wire · Sep 8, 2026Inhibrx Biosciences: Currently conducting phase 1/2 study of Inbrx-106 in perioperative setting of NSCLC, with initial results targeted by mid-2027
AInvest Wire · Sep 8, 2026Inhibrx to explore inbrx-106 with cancer vaccines
AInvest Wire · Sep 8, 2026Inhibrx Biosciences - To expand phase 2 study by 50 HPV+ patients
Inhibrx Biosciences has announced plans to expand its ongoing phase 2 clinical trial by enrolling an additional 50 patients with human papillomavirus-positive (HPV+) cancers. This expansion aims to further evaluate the safety and efficacy of the company’s investigational therapy in treating this…
AInvest Wire · Sep 8, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.